TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B Share Price
Certificat
DE000SU8JW91
| Market Closed - Boerse Frankfurt Warrants 20:38:50 05/07/2024 BST | ||
| 1.18 EUR | -6.35% |
|
| Current month | +34.09% | ||
| 1 month | -5.60% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 1.18 | -6.35% |
| 04/07/24 | 1.26 | -6.67% |
| 03/07/24 | 1.35 | +37.76% |
| 02/07/24 | 0.98 | +34.25% |
| 01/07/24 | 0.73 | -17.05% |
Real-time Boerse Frankfurt Warrants
Last update July 05, 2024 at 08:38 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SU8JW9 |
| ISIN | DE000SU8JW91 |
| Date issued | 05/02/2024 |
| Strike | 1,061 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.5 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.67 € |
|---|---|
| Lowest since issue | 0.43 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974
DKK
Average target price
952.2
DKK
Spread / Average Target
-2.24%
- Stock Market
- Certificates
- Certificat
